iBio (IBIO) Revenue (2011 - 2025)

iBio (IBIO) posted quarterly Revenue of $100000.0 for Q3 2025, down 50.0% quarter-over-quarter from $200000.0 in Q2 2025.

iBio (IBIO) Revenue (2011 - 2025) Analysis & Trends

iBio (IBIO) has reported Revenue for 15 consecutive years, with $100000.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Revenue changed N/A year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $300000.0 (down 20.0% YoY), while the FY2025 annual figure was $400000.0, up 77.78% from the prior year.
Revenue slipped to $100000.0 in Q3 2025 per IBIO's latest filing, from $200000.0 in the prior quarter.
Across five years, Revenue topped out at $1.8 million in Q1 2022 and bottomed at $50000.0 in Q3 2023.
Historically, Revenue has averaged $429444.4 across 5 years, with a median of $200000.0 in 2024.
On a YoY basis, Revenue climbed as much as 696.88% in 2021 and fell as far as 79.51% in 2021.
iBio's Revenue stood at $84000.0 in 2021, then jumped by 2042.86% to $1.8 million in 2022, then sank by 97.22% to $50000.0 in 2023, then jumped by 300.0% to $200000.0 in 2024, then slumped by 50.0% to $100000.0 in 2025.
Business Quant data shows IBIO's Revenue at $100000.0 in Q3 2025, $200000.0 in Q2 2025, and $200000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.29 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	425.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	674.14 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.06 Bn
10	iBio	175.21 Mn	175.21 Mn	-	-

Download Data